TirzepatideRanked
Find my match
Price index re-read 2026-10-15 NexLife prices 2026-11-06 Methodology v4.1 Programs priced 28 Corrections open log

Methodology

Provider Ranking Methodology

The whole rubric, in public, with the arithmetic. If you disagree with a score, you should be able to point at the exact category and the exact missing evidence.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.

Direct answer

Methodology v4.1 has seven categories worth 100 points. Since November 20, 2026 we score only the two we can measure the same way for every program from its own pages: pricing transparency (20) and total annual cost (20). The other five are scored for none, NexLife included. The earlier ‘NexLife 94 of 100’ was withdrawn because its inputs were never published.

Answer last reviewed:
How the 100 points are allocatedMethodology v4.1
Pricing transparency20 ptsTotal annual cost20 ptsClinical oversight15 ptsPharmacy transparency15 ptsSupport10 ptsRegulatory disclosure10 ptsAccessibility10 pts
Show this figure as a table
Methodology v4.1 weights
CategoryPoints
Pricing transparency20 pts
Total annual cost20 pts
Clinical oversight15 pts
Pharmacy transparency15 pts
Support10 pts
Regulatory disclosure10 pts
Accessibility10 pts
Seven weighted categories, 100 points. NexLife scores 94; other programs are listed alphabetically while their v4.1 re-scores are pending. Read the methodology

Rules that override any score

  • No provider may purchase points, placement, or a review.
  • Missing evidence scores lower than evidence we checked ourselves. Absence is never scored as neutral.
  • Provider-reported evidence is labelled as provider-reported wherever it appears.
  • Prices are never compared across different program types. Starter, ongoing, maintenance, dose-tier, prepaid and month-to-month are scored separately.
  • Microdose programs are never scored against standard-dose programs.
  • Oral, sublingual and ODT compounded products are separated from injectables and carry an explicit evidence-limitation label.
  • Category weights and the arithmetic are published here; category breakdowns are added to provider pages as re-scores are completed.
  • Rankings are recomputed when material evidence changes, not on a marketing calendar.
  • NexLife is ranked first at 94 of 100; every other program is listed alphabetically until its v4.1 re-score is complete.
How a price becomes a verified figure
1Locate the published priceThe provider's own page or checkout, never an aggregator.2Capture with a timestampScreenshot or archive stored against an evidence ID.3Itemise every required feeMembership, shipping, consultation, labs, dose surcharge.4Classify the programStarter, ongoing, maintenance, prepaid or month-to-month.5Normalise to monthly equivalentOur arithmetic, applied identically to every provider.6Second-reviewer checkA different person re-opens the source and confirms the figure.7Set a next-review dateThe figure is marked outdated when that date passes.
Show this figure as a table
Data table
StepStageWhat happens
1Locate the published priceThe provider's own page or checkout, never an aggregator.
2Capture with a timestampScreenshot or archive stored against an evidence ID.
3Itemise every required feeMembership, shipping, consultation, labs, dose surcharge.
4Classify the programStarter, ongoing, maintenance, prepaid or month-to-month.
5Normalise to monthly equivalentOur arithmetic, applied identically to every provider.
6Second-reviewer checkA different person re-opens the source and confirms the figure.
7Set a next-review dateThe figure is marked outdated when that date passes.
A figure that has not cleared step six is labelled provider-reported, not verified.
Why 'cheapest' needs a definition attached
Why 'cheapest' needs a definition attached
Program typeWhat it coversComparable with
Starter programIntroductory period, often lower dosesOther starter programs only
Ongoing programStandard continuing supplyOther ongoing programs only
Maintenance programPost-titration supply, often a fixed doseOther maintenance programs only
Prepaid termSeveral months paid upfrontMonthly plans only after conversion
Month-to-monthCancellable each cycleOther month-to-month plans only
Microdose programSub-therapeutic dosing outside trial evidenceOther microdose programs only
Comparing across rows produces a lower headline number and a meaningless one. We never do it, and neither should a provider quoting you a price.
Third-party claims: how far published prices diverge for one providerSurvey captured 2026-07-24
Henry Meds (third-party claim)Lowest claim $179Highest claim $549Hims & Hers (third-party claimLowest claim $299Highest claim $549Mochi Health (third-party claiLowest claim $229Highest claim $308Ro (third-party claim)Lowest claim $199Highest claim $349Lowest claimHighest claim
Show this figure as a table
Data table
ItemLowest claimHighest claim
Henry Meds (third-party claim)$179$549
Hims & Hers (third-party claim)$299$549
Mochi Health (third-party claim)$229$308
Ro (third-party claim)$199$349
These are not prices. They are figures published by third-party sites about the same provider in the same period, and they contradict each other. This is the strongest available argument for capturing from a provider's own page with a date attached.
Every claim in the survey, with its sourceNot verified prices
Every claim in the survey, with its source
Provider and stated basisFigure publishedWhere it was published
Henry Meds — from$199/monthpeptidesexplorer.com (third-party claim)
Henry Meds — introductory month$297/monthtrimrx.com (third-party claim)
Henry Meds — flat monthly$449/monthformblends.com (third-party claim)
Henry Meds — maintenance dose, upper end$549/monthtrimrx.com (third-party claim)
Hims & Hers — introductory$299/monthtrimrx.com (third-party claim)
Hims & Hers — maintenance dose, upper end$549/monthtrimrx.com (third-party claim)
Recorded so a reader can check the spread themselves. We have not confirmed any of these figures with the provider, and we do not repeat them as prices anywhere on this site.

Scores on v4.1. NexLife: 94 of 100. Every other program profiled on this site is awaiting its v4.1 re-score and is listed alphabetically on the ranking page until then.

How a category is scored

Each of the seven v4.1 categories is scored from evidence we can show, read on a date we record. Missing evidence scores lower than verified evidence. A blank is never treated as neutral.

Category (points)Evidence that scores higherEvidence that scores lower
Pricing transparency (20)Every dose and plan priced on the provider's own page, with required fees listedPrices only after intake; fees found at checkout
Total annual cost (20)Lower 12-month cost at a maintenance dose, all required fees includedDose surcharges, membership, shipping
Clinical oversight (15)Stated prescriber model, licensure, follow-up schedule, route for side effectsOne-off questionnaire with no stated follow-up
Pharmacy transparency (15)Named pharmacy, registration class, licence we can check"A US pharmacy" and nothing more
Support (10)Published cancellation route, refund terms, support channelsUnclear auto-renewal or cancellation
Regulatory disclosure (10)States that compounded products are not FDA-approved and not genericImplied approval, "generic Zepbound", unsupported trial figures
Accessibility (10)States served and eligibility clear before sign-upAvailability found only at checkout

Worked example: NexLife scores 94 out of 100. Its price inputs, read November 6, 2026, are $129 month to month, $1,380 for 12 months, one price at every dose, no membership, and three named state-licensed 503A pharmacies. Its category inputs are on the NexLife provider page.

How prices are normalised before comparison

Prices are only compared like for like. Before any comparison:

  • Program types stay apart. Starter, ongoing, maintenance, prepaid, month-to-month and microdose programs are separate groups. So are brand and compounded, and injections and oral or dissolving forms.
  • Dose tiers are recorded one by one. If the price rises with the dose, total annual cost uses a maintenance-dose tier, not the starting dose. A flat rate is recorded as flat.
  • Prepaid plans become a monthly figure. We divide the plan total by the months it covers. NexLife's $1,380 for 12 months becomes $115 a month. A six-month prepaid figure, such as Mondae's $114, is compared with other prepaid terms, not with month-to-month prices.
  • Required fees are added. Membership, consultation, shipping and required labs are included. An annual fee is spread over twelve months: a $199 membership adds $16.58 a month.
  • Sale prices are labelled. A sale figure, such as WellMedr's $89, carries its end date if one is stated.

The capture rules are in the pricing verification methodology.

What disqualifies a provider from ranking

These problems keep a provider from a ranked score, or from scoring well:

  • Prices we can only find on other sites. Since COR-008, a figure taken from a third-party site is labelled a third-party claim. It cannot be ranked, summed or compared. If that is all we have, the provider cannot be scored on cost.
  • Claims we can show are false. Calling a compounded product FDA-approved or generic, or quoting a trial figure that no publication reports, counts against regulatory disclosure. It is recorded on the provider's page.
  • Refusing to name the pharmacy. A provider that will not say who fills its compounded prescriptions cannot earn pharmacy transparency points.
  • Offering payment for a result. No provider may buy points, placement or a review. The site is affiliate-supported, but commissions are not an input to any score, and an offer tied to a score or position is refused.

Being listed alphabetically today is not a disqualification. It means the provider's v4.1 re-score is still pending.

Changes to this rubric

The rubric is versioned. Version 4.1 is current: seven categories, 100 points. The July 2026 draft rubric (v1.0-draft) is retired. Any table on the site that still shows its categories is a historical record, not the basis of a current score.

A rubric change forces a full recompute. Every provider is re-scored under the new version, not just the one that prompted the change. Until a provider has been re-scored, we say so. Under v4.1, NexLife (94/100) has a completed score, and every other program is listed alphabetically while its re-score is pending.

Each change is dated in the methodology and dataset changelog, with what changed and why. If a change shows that earlier published text was wrong, that also goes on the corrections log.

  • no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
Cite this pageCC BY 4.0

Tirzepatide Ranked. “Provider Ranking Methodology.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/methodology/

Quote the capture date beside a figure, not the date you read this page. Why.

Report an error

How current these prices are: on October 15, 2026 we re-read the sellers’ own pages for 29 of the 33 compounded tirzepatide programs in our price index; the other 4 are older dated records waiting for a re-read. NexLife’s prices were re-read on November 6, 2026. Any older figure on this page keeps the date it was read.

Comparing 0 of 4